公开(公告)号：US11672830B2

公开(公告)日：2023-06-13

申请号：US16093689

申请日：2017-04-17

Applicant: Temple University—Of The Commonwealth System of Higher Education

Inventor： Mohsin Khan ,  Raj Kishore

IPC: A61K35/34 ,  C12N5/077 ,  C12N15/113

CPC classification number: A61K35/34 ,  C12N5/0657 ,  C12N15/113 ,  C12N2310/141 ,  C12N2501/65

Abstract: The invention provides one or more of miR-290 family and Lin28a modified cardiac progenitor cell based therapies for the treatment of myocardial infarction. Exosomes derived from one or more of miR-290 family and Lin28a modified cardiac progenitor cells can also be used in cardiac therapy.

公开(公告)号：US11666604B2

公开(公告)日：2023-06-06

申请号：US15779073

申请日：2017-12-18

Applicant: INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION ,  AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Young-Il Yang ,  Ki-Dong Park ,  Won-Jin Lee ,  Min-Young Choi ,  Kyung-Min Park ,  Yun-Ki Lee

IPC: A61K35/34 ,  C12N5/0775

CPC classification number: A61K35/34 ,  C12N5/0662 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/17 ,  C12N2501/235 ,  C12N2533/52 ,  C12N2533/54 ,  C12N2533/56

Abstract: Disclosed are a multilayered cell sheet of cardiac stem cells (CSCs) and a method of manufacturing the same. In particular, the present disclosure provides a method of manufacturing a multilayered cell sheet according to a single step culture procedure by using, as a three-dimensional matrix, a biodegradable natural polymer hydrogel and embedding CSCs in the hydrogel. The multilayered cell sheet of the present disclosure does not require any special device for the manufacturing, is manageable with good physicomechanical property, increases a cell engraftment rate after transplantation based on sufficient accumulation of various growth and protective factors and extracellular matrix between cells, and is also self-assembled by the cell-mediated hydrogel compaction, making nutrients transfer easy. Therefore, the multilayered cell sheet of the CSCs is expected to be usefully applicable as a therapeutic agent for myocardium regeneration.

公开(公告)号：US11648279B2

公开(公告)日：2023-05-16

申请号：US16973625

申请日：2019-05-09

Applicant: KYOTO UNIVERSITY ,  SANYO CHEMICAL INDUSTRIES, LTD.

Inventor： Yoshinori Yoshida ,  Takeshi Hatani ,  Ryosuke Suzuki ,  Shingo Kawabata

IPC: A61K35/34 ,  A61K38/16

CPC classification number: A61K35/34 ,  A61K38/164

Abstract: Provided are a composition for cell transplant and a method for cell transplant, both of which enable a myocardial tissue to favorably retain cardiac myocytes and/or cardiac progenitors and can improve the persistence and proliferation of transplanted cells. The composition for cell transplant of the present invention is a composition for cell transplant, containing cells and an aqueous solution containing a protein (A), the cells including a cardiac myocyte and/or a cardiac progenitor, the protein (A) having a degree of hydrophobicity of 0.2 to 1.2, the protein (A) containing a polypeptide chain (Y) and/or a polypeptide chain (Y′), the protein (A) containing 1 to 100 polypeptide chains as a total of the polypeptide chain (Y) and the polypeptide chain (Y′), the polypeptide chain (Y) being a polypeptide chain having 2 to 100 continuous amino acid sequences (X), the amino acid sequence (X) having any one of a VPGVG sequence (1) corresponding to an amino acid sequence of SEQ ID NO: 1, a GVGVP sequence (2) corresponding to an amino acid sequence of SEQ ID NO: 2, a GPP sequence, a GAP sequence, and a GAHGPAGPK sequence (3) corresponding to an amino acid sequence of SEQ ID NO: 3, the polypeptide chain (Y′) being a polypeptide chain having a structure in which 0.1 to 5% amino acid residues in the polypeptide chain (Y) are replaced by a lysine residue and/or an arginine residue and including 1 to 100 residues as a total of the lysine residue and the arginine residue.

公开(公告)号：US20190216858A1

公开(公告)日：2019-07-18

申请号：US16297085

申请日：2019-03-08

Applicant: Peter K. Law

Inventor： Peter K. Law

IPC: A61K35/34 ,  A61P35/00

CPC classification number: A61K35/34 ,  A61P35/00

Abstract: A composition having a quantum of genetically normal non-host myoblasts and host serum, wherein the composition is adapted to induce myoblast proliferation. Also, disclosed is a method for inhibiting growth of a cancer tumor in a host and/or preventing cancer cells from metastasis in a host.

公开(公告)号：US20190211362A1

公开(公告)日：2019-07-11

申请号：US16312651

申请日：2017-06-27

Applicant: CRISPR THERAPEUTICS AG

Inventor： Ante Sven LUNDBERG ,  Samarth KULKARNI ,  Lawrence KLEIN ,  Hari Kumar PADMANABHAN

IPC: C12N15/90 ,  C12N15/10 ,  C12N9/22 ,  A61K35/34 ,  A61K38/46 ,  C12N15/11

CPC classification number: C12N15/907 ,  A61K35/34 ,  A61K38/465 ,  C12N9/22 ,  C12N15/102 ,  C12N15/11 ,  C12N15/113 ,  C12N2310/20 ,  C12N2750/14143 ,  C12N2800/80

Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with DMPK whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of DMPK gene in a cell by genome editing.

公开(公告)号：US20190153391A1

公开(公告)日：2019-05-23

申请号：US15511275

申请日：2015-09-14

Applicant: OSAKA UNIVERSITY

Inventor： Yukiko OCHI ,  Kiyotoshi SEKIGUCHI ,  Shigeru MIYAGAWA ,  Yoshiki SAWA ,  Antti Markus SILTANEN

IPC: C12N5/077 ,  C12N5/074 ,  A61K35/34

CPC classification number: C12N5/0657 ,  A61K35/34 ,  C12N5/0696 ,  C12N2506/45 ,  C12N2533/52

Abstract: The present invention provides a method for preparing a clinically applicable, safe and less damaged cardiomyocyte population through a brief and simple procedure from a cell population obtained by induced differentiation of pluripotent stem cells into cardiomyocytes. The present invention relates to a method for preparing a cardiomyocyte population, the method comprising the steps of: (1) inducing pluripotent stem cells to differentiate into cardiomyocytes, (2) bringing a cell population obtained by the induced differentiation into contact with a laminin selected from the group consisting of laminin α2β1γ1, laminin α2β2γ1, laminin α1β1γ1 and laminin α1β2γ1, or a fragment thereof having integrin binding activity, and (3) retrieving cells adherent to the laminin or the laminin fragment.

公开(公告)号：US20190022017A1

公开(公告)日：2019-01-24

申请号：US16140578

申请日：2018-09-25

Applicant: Technion Research & Development Foundation Limited

Inventor： Marcelle MACHLUF ,  Deborah CHAIMOV

IPC: A61K9/50 ,  A61K35/407 ,  A61K35/39 ,  A61K35/12 ,  A61K35/34

CPC classification number: A61K9/5063 ,  A61K9/5015 ,  A61K9/5036 ,  A61K9/5089 ,  A61K35/12 ,  A61K35/34 ,  A61K35/39 ,  A61K35/407

Abstract: A microparticle for cell encapsulation is provided, having a core which comprises continuous fibers of decellularized extracellular matrix (ECM) and, optionally, an outer layer. Also provided are methods of encapsulating cells in the microparticle, pharmaceutical compositions comprising the microparticle, and methods of treating disease in animals employing the microparticles of the invention, for example, treating Diabetes.

公开(公告)号：US20180346879A1

公开(公告)日：2018-12-06

申请号：US15568274

申请日：2016-04-22

Applicant: GENEA IP HOLDINGS PTY LIMITED

Inventor： Uli SCHMIDT ,  Leslie CARON

IPC: C12N5/077 ,  A61K35/34 ,  G01N33/50

CPC classification number: A61K35/34 ,  A61K35/545 ,  C12N5/0658 ,  C12N2510/00

Abstract: Methods and compositions for producing cells expressing CD56/Pax3, CD56Pax7, and/or Pax3/Pax7 are provided herein. In some instances, the method involves contacting a pluripotent stem cell in an in vitro culture with one compound, or with two or more compounds at the same time, wherein the contacting the pluripotent stem cell in the in vitro culture with one compound, or with two or more compounds at the same time, directly results in generation of cells expressing CD56/Pax3, CD56/Pax7, or Pax3/Pax7. Also provided are methods of using the generated cells. Typically one of the compounds is a wnt pathway activator, such as the GSK3 inhibitor CHIR99021.

公开(公告)号：US20180214604A1

公开(公告)日：2018-08-02

申请号：US15938706

申请日：2018-03-28

Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES

Inventor： Anthony Atala ,  James Yoo ,  In Kap Ko

IPC: A61L27/36 ,  A61L27/38 ,  A61K35/34 ,  A61K38/18 ,  A61K45/06 ,  A61K47/34 ,  A61K47/42 ,  A61L27/18 ,  C12N5/077 ,  C12N5/00 ,  A61L27/54 ,  A61L27/24 ,  A61K9/00

CPC classification number: A61L27/3604 ,  A61K9/0034 ,  A61K35/34 ,  A61K38/18 ,  A61K45/06 ,  A61K47/34 ,  A61K47/42 ,  A61L27/18 ,  A61L27/24 ,  A61L27/3683 ,  A61L27/3687 ,  A61L27/3834 ,  A61L27/54 ,  A61L2300/414 ,  A61L2400/06 ,  A61L2430/30 ,  C12N5/0062 ,  C12N5/0659 ,  C12N2513/00 ,  C12N2533/30 ,  C12N2533/54 ,  A61K2300/00 ,  C08L67/04

Abstract: The invention is directed to methods and compositions for obtaining uniform sized muscle fiber fragments for transplantation. These muscle fiber fragments are able to reconstitute into long fibers that are oriented along native muscle. The implanted muscle cells integrate with native vascular and neural network, as confirmed by histology and immunohistochemistry. This invention is particularly advantageous because autologous muscle can be harvested from a donor site, processed and injected into target sites in the operating room. The fragmented muscle fibers can be readily integrated within the host.

公开(公告)号：US20180200244A1

公开(公告)日：2018-07-19

申请号：US15915637

申请日：2018-03-08

Applicant: The Regents of the University of California

Inventor： Nipavan CHIAMVIMONVAT ,  Bruce D. HAMMOCK

IPC: A61K31/4468 ,  A61K31/4465 ,  A61L31/16 ,  A61L31/00 ,  A61K35/34 ,  A61K31/336 ,  A61K31/195 ,  A61K35/545 ,  A61K9/70 ,  A61K35/28 ,  A61K31/17 ,  A61K31/197 ,  A61K31/22 ,  A61K31/415

CPC classification number: A61K31/4468 ,  A61K9/7023 ,  A61K31/17 ,  A61K31/195 ,  A61K31/197 ,  A61K31/22 ,  A61K31/336 ,  A61K31/415 ,  A61K31/4465 ,  A61K35/28 ,  A61K35/34 ,  A61K35/545 ,  A61L31/005 ,  A61L31/16 ,  A61L2300/432 ,  A61L2300/64 ,  A61L2430/20 ,  A61K2300/00

Abstract: Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.